Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN124 phase 1/2 study in polycythemia vera
2023-503544-13-00Phase 2Authorised
- Sponsor
- Silence Therapeutics
- Start
- Nov 2023
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of SLN124 in polycythemia vera (PV) (3 arms), sponsored by Silence Therapeutics. Primary endpoints: Safety assessment, Tolerability and 2 more. Planned start Nov 2023; status: authorised.
02
Drugs
SLN124
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2023-503544-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503544-13-00.